Mefoxil 1g/Vial

Cefoxitin Sodium, the active ingredient in Mefoxil, is a second‑generation cephalosporin presented as a 1 g injection for intravenous and intramuscular use. It treats a broad spectrum of bacterial infections, including respiratory, urinary, skin and soft‑tissue, and intra‑abdominal infections, in both adult and pediatric patients.

GNH USA supplies Mefoxil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Customer support includes pharmacovigilance assistance and cold‑chain logistics where required.

Cefoxitin Sodium is a second‑generation cephalosporin antibiotic used to treat infections caused by susceptible bacteria.

- Respiratory tract infections: effective for community‑acquired pneumonia and acute bronchitis caused by susceptible organisms. - Urinary tract infections: used to eradicate Gram‑negative uropathogens in uncomplicated and complicated UTIs. - Skin and soft tissue infections: treats cellulitis, wound infections, and abscesses due to susceptible bacteria. - Intra‑abdominal infections: indicated for peritonitis, intra‑abdominal abscesses, and postoperative infections.

Cefoxitin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate watery stools. - Nausea: occasional feeling of queasiness. - Vomiting: transient episodes. - Injection site pain: discomfort at the IV or IM site. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Stevens‑Johnson syndrome: rare severe skin and mucous membrane disorder. - Clostridioides difficile‑associated diarrhea: severe colitis following antibiotic use. - Neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet levels leading to bleeding risk. - Acute renal impairment: sudden decline in kidney function.

Prior to initiating therapy with Cefoxitin Sodium, clinicians should consider several safety precautions to minimize risk. - Allergy assessment: verify no known hypersensitivity to cephalosporins or penicillins. - Renal function monitoring: check creatinine clearance and adjust dose in renal impairment. - Hepatic function monitoring: observe liver enzymes in patients with liver disease. - Concomitant nephrotoxic drugs: use caution when combined with other renal‑toxic agents. - Pregnancy and lactation: avoid unless benefits outweigh potential risks, as safety data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Cefoxitin Sodium can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity when used together. - Loop diuretics: heightened ototoxic potential. - Warfarin: potentiation of anticoagulant effect, may raise INR. - Probenecid: reduces renal excretion of cefoxitin, increasing plasma levels. - Live bacterial vaccines: may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal effectiveness. - Antacids containing aluminum or magnesium: may affect absorption if given orally. - NSAIDs: concurrent use may impair renal function, especially in compromised patients.